Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN- in promyelocytic cells
Open Access
- 29 September 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 20 (11) , 1457-1466
Abstract
The human promyelocytic cell line THP-1 expresses high level of HLA class II (HLA-II) molecules after IFN-γ treatment. Here, we report a variant of THP-1 that does not express HLA-II after IFN-γ. The variant's HLA-II phenotype is constant over time in culture and it is not related to a defective IFN-γ-signalling pathway. Transfection of CIITA, the HLA-II transcriptional activator, under the control of a cytomegalovirus promoter rescues high level of HLA-DR surface expression in the variant indicating that the biosynthetic block resides in the expression of CIITA and not in the CIITA-dependent transactivation of the HLA-II promoters. Treatment of the variant with 5-azacytidine (5-aza), which inhibits CpG methylation, restores inducibility of HLA-II by IFN-γ both at transcriptional and phenotypic level and antigen presenting and processing function of the variant. DNA studies demonstrate that the molecular defect of the THP-1 variant originates from the methylation of the CIITA promoter IV. Furthermore, treatment with 5-aza produces a substantial demethylation of CIITA promoter IV and a significant increase of IFN-γ-dependent HLA-II expression in another myelomonocytic cell line, U937. Therefore hyper-methylation of CIITA promoter IV may be a relevant mechanism of epigenetic control preventing HLA-II IFN-γ inducibility in the myelomonocytic cell lineage.Keywords
This publication has 37 references indexed in Scilit:
- An interferon‐sensitive response element is involved in constitutive caspase‐8 gene expression in neuroblastoma cellsInternational Journal of Cancer, 2006
- CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor MemoryClinical Cancer Research, 2006
- Epigenetic Modulation of Solid Tumors as a Novel Approach for Cancer ImmunotherapySeminars in Oncology, 2005
- The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cellsEuropean Journal of Immunology, 2005
- Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-γ-induced HLA-DR expression in colorectal and gastric cancer cellsOncogene, 2004
- Interferon-γ: an overview of signals, mechanisms and functionsJournal of Leukocyte Biology, 2003
- Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cellsEuropean Journal of Immunology, 2003
- Activation of the MHC Class II Transactivator CIITA by Interferon-γ Requires Cooperative Interaction between Stat1 and USF-1Immunity, 1998
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.Journal of Experimental Medicine, 1994
- The Biochemistry and Cell Biology of Antigen Processing and PresentationAnnual Review of Immunology, 1993